DI
ABBV icon

DAGCO Inc’s AbbVie ABBV Stock Holding History

DAGCO Inc’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Buy
9,479
+1,107
+13% +$238K 0.44% 39
2026
Q1 		$1.82M Sell
8,372
-35
-0.4% -$7.76K 0.39% 40
2025
Q4 		$1.92M Buy
8,407
+5
+0.1% +$1.14K 0.44% 38
2025
Q3 		$1.95M Buy
8,402
+7
+0.1% +$1.43K 0.49% 34
2025
Q2 		$1.56M Buy
8,395
+7
+0.1% +$1.3K 0.43% 38
2025
Q1 		$1.76M Sell
8,388
-190
-2% -$36.9K 0.57% 34
2024
Q4 		$1.52M Buy
8,578
+568
+7% +$104K 0.5% 36
2024
Q3 		$1.58M Sell
8,010
-56
-0.7% -$10.5K 0.65% 31
2024
Q2 		$1.38M Sell
8,066
-7
-0.1% -$1.16K 0.61% 34
2024
Q1 		$1.47M Buy
8,073
+7,847
+3,472% +$1.35M 0.67% 35
2023
Q4 		$35K Sell
226
-8,214
-97% -$1.2M 0.03% 129
2023
Q3 		$1.26M Buy
8,440
+7
+0.1% +$1.03K 0.65% 38
2023
Q2 		$1.14M Buy
8,433
+8
+0.1% +$1.17K 0.57% 42
2023
Q1 		$1.34M Buy
8,425
+7
+0.1% +$1.07K 0.72% 38
2022
Q4 		$1.36M Buy
8,418
+7
+0.1% +$1.07K 0.8% 37
2022
Q3 		$1.13M Sell
8,411
-93
-1% -$13.3K 0.71% 39
2022
Q2 		$1.3M Buy
8,504
+6
+0.1% +$917 0.67% 40
2022
Q1 		$1.33M Buy
8,498
+7
+0.1% +$1.02K 0.6% 46
2021
Q4 		$1.15M Buy
8,491
+8
+0.1% +$945 0.45% 58
2021
Q3 		$915K Sell
8,483
-216
-2% -$24.7K 0.39% 61
2021
Q2 		$980K Buy
8,699
+9
+0.1% +$1.01K 0.44% 59
2021
Q1 		$940K Buy
8,690
+10
+0.1% +$1.07K 0.47% 58
2020
Q4 		$930K Sell
8,680
-41
-0.5% -$3.94K 0.52% 56
2020
Q3 		$764K Buy
8,721
+9
+0.1% +$847 0.52% 59
2020
Q2 		$855K Sell
8,712
-390
-4% -$34.3K 0.86% 45
2020
Q1 		$693K Buy
9,102
+10
+0.1% +$852 0.75% 49
2019
Q4 		$805K Sell
9,092
-166
-2% -$13.8K 0.71% 54
2019
Q3 		$701K Sell
9,258
-6,943
-43% -$476K 0.7% 55
2019
Q2 		$1.18M Sell
16,201
-465
-3% -$36.5K 1.24% 27
2019
Q1 		$1.34M Sell
16,666
-591
-3% -$48.3K 1.45% 21
2018
Q4 		$1.59M Buy
+17,257
New +$1.52M 1.97% 12

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

DAGCO Inc's ABBV Position: Q2 2026 in Review

DAGCO Inc increased its AbbVie (ABBV) stake by 13% in Q2 2026, buying an estimated $238K and bringing the position to 9,479 shares worth $2.39M. The position accounts for 0.44% of the portfolio, ranked #39.

DAGCO Inc first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 1,316 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • DAGCO Inc held 9,479 shares of AbbVie worth $2.39M as of Q2 2026.
  • DAGCO Inc bought 1,107 AbbVie shares in Q2 2026, an estimated $238K.
  • AbbVie made up 0.44% of DAGCO Inc's portfolio in Q2 2026, its #39 holding.
  • DAGCO Inc first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
  • 1,316 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on DAGCO Inc's 13F filing for Q2 2026, filed 10 Jul 2026.